Does Rallies show Form 4 insider transactions for GLSI?

Yes. Rallies tracks GLSI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is GLSI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GLSI. It does not provide personalized investment advice.

GLSI (Greenwich LifeSciences, Inc.) Stock Analysis - Insider Trades

Greenwich LifeSciences, Inc. (GLSI) is a publicly traded Healthcare sector company. As of May 21, 2026, GLSI trades at $26.82 with a market cap of $372.41M and a P/E ratio of -22.14. GLSI moved +3.57% today. Year to date, GLSI is +28.81%; over the trailing twelve months it is +165.24%. Its 52-week range spans $7.78 to $34.10. Analyst consensus is buy with an average price target of $47.50. Rallies surfaces GLSI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading GLSI stock inside the company?

Recent GLSI insider activity includes Patel Snehal bought 1.80K, Patel Snehal bought 2.90K, Patel Snehal bought 4.30K, Patel Snehal bought 2.90K, and Patel Snehal bought 4.10K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

GLSI Key Metrics

Key financial metrics for GLSI
Metric	Value
Price	$26.82
Market Cap	$372.41M
P/E Ratio	-22.14
EPS	$-1.21
Dividend Yield	0.00%
52-Week High	$34.10
52-Week Low	$7.78
Volume	816
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-15.79M
Gross Margin	0.00%

Recent GLSI Insider Trades

Patel Snehal bought 1.80K (~$53.69K) on Jan 13, 2026.
Patel Snehal bought 2.90K (~$79.87K) on Jan 12, 2026.
Patel Snehal bought 4.30K (~$91.85K) on Dec 31, 2025.
Patel Snehal bought 2.90K (~$63.02K) on Dec 30, 2025.
Patel Snehal bought 4.10K (~$51.74K) on Dec 18, 2025.

Latest GLSI News

Greenwich LifeSciences delays FY2025 10-K, FLAMINGO-01 arm shows 70-80% recurrence drop — Apr 30, 2026
Greenwich LifeSciences Reports 70-80% Recurrence Reduction Data in 250 Patients — Apr 23, 2026
Greenwich LifeSciences Raises Cash to $10.5M; Phase III Arm Shows 70–80% Recurrence Reduction — Apr 14, 2026
Greenwich LifeSciences Files Patent Claims to Double GP2 Market to 88,000 Patients — Apr 7, 2026
Greenwich LifeSciences Expands FLAMINGO-01 Trial to Up to 200 Sites with City of Hope — Mar 19, 2026

GLSI Analyst Consensus

2 analysts cover GLSI: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $47.50.

Common questions about GLSI

Who is trading GLSI stock inside the company?: Recent GLSI insider activity includes Patel Snehal bought 1.80K, Patel Snehal bought 2.90K, Patel Snehal bought 4.30K, Patel Snehal bought 2.90K, and Patel Snehal bought 4.10K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for GLSI?: Yes. Rallies tracks GLSI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is GLSI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GLSI. It does not provide personalized investment advice.